The Focus Remains On ABcann Global Corp (CVE:PDA.H)

ABcann Global Corp (CVE:PDA.H) has been an approved cultivator since 2014. It spent the initial 4 years and significant resources on R&D, perfecting its cultivation procedure with the assistance of the Controlled Environmental System Research Facility. Currently, every variable in company’s growing, harvesting and curing procedure is monitored and controlled by computer. This indoor, advanced growing environment has led in a superior offering that’s clean, repeatable and consistent; qualities that patients and physicians are looking for.

The highlights

A standardized and clean offering is vital because of the changing impact the medication can have on pot users, who never actually discern the quality of what they are purchasing. ABcann offerings are the same quality item every time. Dr. Michael Dixon reported that the challenge is to consistently standardize the environmental experience for the crops, so they all behave similarly and manufacture the same medical compounds. The only means to achieve that is to cultivate crops in an extremely precisely controlled, reproducible and predictable manner.

ABcann, while sluggish to go public compared to some of its peers, is opting now from a position of fervor, ability and strength, and the skill to back its claims to lead the market. Since it started selling offerings in June 2016, the firm can’t match up with demand, with an increasing pace of 30%, month over month. Its client retention rate is 94.7%.

Ken Clement, the Executive Chairman and Founder of ABcann, said that the patient demand at the beginning of the year has increased. To keep up, they need to expand, and that’s the reason they are going public. They intend to become one of the leading firms in the country. ABcann is in the course of raising as much as $8 million in equity from the Initial Public Offering and projects to become one of the leading manufacturers in Canada.